Latvija - latviešu - Zāļu valsts aģentūra

stada arzneimittel ag, germany - fingolimods - kapsula, cietā - 0,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - fingolimods - kapsula, cietā - 0,25 mg

Latvija - latviešu - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - fingolimods - kapsula, cietā - 0,5 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomīds - multiplā skleroze - selective immunosuppressants - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridīns - multiplā skleroze - other nervous system drugs - fampyra tiek norādīts uzlabošanas pieaugušiem pacientiem ar multiplo sklerozi iešana ar kājām invaliditātes (paplašināts invaliditātes statusa skalas 4-7).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiplā skleroze - selective immunosuppressants - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hidrohlorīds - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imūnsupresanti - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridīns - multiplā skleroze - other nervous system drugs - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).